Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
12.18.2007
the latest edition of the Spanish journal of health economics is out..
Topics in this edition: Spanish NHS and healthcare cost optimization, cost-effectiveness of HPV vaccination in Spain, QoL in coronary syndrom patients, discussion around NICE and diabetes drugs etc. You can read all articles online..
No comments:
Post a Comment